• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Updated meta-analysis of randomized controlled trials on the safety and efficacy of different prophylactic anticoagulation dosing regimens in non-critically ill hospitalized patients with COVID-19.关于非重症COVID-19住院患者不同预防性抗凝给药方案安全性和有效性的随机对照试验的更新荟萃分析。
Eur Heart J Cardiovasc Pharmacother. 2022 May 5;8(3):E15-E17. doi: 10.1093/ehjcvp/pvac010.
2
Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials.不同预防性抗凝剂量方案在 COVID-19 危重症和非危重症患者中的安全性和有效性：一项随机对照试验的系统评价和荟萃分析。
Eur Heart J Cardiovasc Pharmacother. 2022 Sep 29;8(7):677-686. doi: 10.1093/ehjcvp/pvab070.
3
In COVID-19, escalated- vs. prophylactic-dose anticoagulation does not reduce mortality and increases major bleeding.在 COVID-19 中，强化剂量与预防剂量的抗凝治疗均不能降低死亡率，反而会增加大出血风险。
Ann Intern Med. 2022 Feb;175(2):JC18. doi: 10.7326/J21-0021. Epub 2022 Feb 1.
4
[COVID-19, anticoagulation and venous thromboembolism: what have we learned ?].[新型冠状病毒肺炎、抗凝与静脉血栓栓塞：我们学到了什么？]
Rev Med Suisse. 2021 Dec 8;17(762):2140-2144.
5
Venous Thromboembolism in Hospitalized COVID-19 Patients.住院 COVID-19 患者中的静脉血栓栓塞症。
Am J Ther. 2020 Nov/Dec;27(6):e599-e610. doi: 10.1097/MJT.0000000000001295.
6
The effect of higher-intensity dosing of anticoagulation on the clinical outcomes in hospitalized patients with COVID-19: A meta-analysis of randomized controlled trials.高强度抗凝治疗对 COVID-19 住院患者临床结局的影响：一项随机对照试验的荟萃分析。
J Infect Chemother. 2022 Feb;28(2):257-265. doi: 10.1016/j.jiac.2021.11.008. Epub 2021 Nov 17.
7
The standard of care is standard for a reason: Commentary on "Optimal dosing of heparin for prophylactic anticoagulation in critically ill COVID-19 patients: A systematic review and Meta-analysis of randomized clinical trials".医疗标准之所以成为标准：对“危重症COVID-19患者预防性抗凝治疗的肝素最佳剂量：随机临床试验的系统评价和Meta分析”的评论
J Crit Care. 2023 Oct;77:154345. doi: 10.1016/j.jcrc.2023.154345. Epub 2023 May 25.
8
Role of anticoagulation in lowering the mortality in hospitalized covid-19 patients: Meta-analysis of available literature.抗凝在降低住院 COVID-19 患者死亡率中的作用：现有文献的荟萃分析。
Saudi Med J. 2022 Jun;43(6):541-550. doi: 10.15537/smj.2022.43.6.20220046.
9
The management of venous thromboembolism in hospitalized patients with COVID-19.COVID-19 住院患者静脉血栓栓塞症的管理。
Blood Adv. 2020 Aug 25;4(16):4028. doi: 10.1182/bloodadvances.2020002496.
10
Anticoagulation for COVID-19 Patients: A Bird's-Eye View.COVID-19 患者的抗凝治疗：鸟瞰。
Clin Appl Thromb Hemost. 2021 Jan-Dec;27:10760296211039288. doi: 10.1177/10760296211039288.

引用本文的文献

1
The effect of anti-coagulation dosage on the outcome of hospitalized COVID-19 patients in Ethiopia: a multi-center retrospective cohort study.抗凝剂量对埃塞俄比亚住院 COVID-19 患者结局的影响：一项多中心回顾性队列研究。
BMC Pulm Med. 2023 Mar 13;23(1):85. doi: 10.1186/s12890-023-02375-x.
2
One-year cardiovascular outcomes after coronavirus disease 2019: The cardiovascular COVID-19 registry.新冠肺炎后一年的心血管结局：心血管 COVID-19 注册研究。
PLoS One. 2022 Dec 30;17(12):e0279333. doi: 10.1371/journal.pone.0279333. eCollection 2022.
3
Incidence of Venous Thromboembolism in Hospitalized COVID-19 Patients Receiving Thromboprophylaxis.接受血栓预防治疗的住院COVID-19患者静脉血栓栓塞的发生率。
J Hematol. 2022 Oct;11(5):167-175. doi: 10.14740/jh1036. Epub 2022 Oct 31.
4
Effect of therapeutic versus prophylactic anticoagulation therapy on clinical outcomes in COVID-19 patients: a systematic review with an updated meta-analysis.治疗性抗凝治疗与预防性抗凝治疗对COVID-19患者临床结局的影响：一项系统评价及更新的荟萃分析
Thromb J. 2022 Aug 23;20(1):47. doi: 10.1186/s12959-022-00408-9.
5
Anticoagulation in hospitalized patients with COVID-19.COVID-19 住院患者的抗凝治疗。
Blood. 2022 Aug 25;140(8):809-814. doi: 10.1182/blood.2021014527.
6
Thromboprophylaxis and anticoagulation for inpatients with COVID-19 in 2022 and beyond.2022年及以后COVID-19住院患者的血栓预防与抗凝治疗
Clin Microbiol Infect. 2022 Sep;28(9):1184-1186. doi: 10.1016/j.cmi.2022.05.027. Epub 2022 May 29.

本文引用的文献

1
Therapeutic versus Prophylactic Bemiparin in Hospitalized Patients with Nonsevere COVID-19 Pneumonia (BEMICOP Study): An Open-Label, Multicenter, Randomized, Controlled Trial.伴有非重症 COVID-19 肺炎住院患者的治疗用与预防用比伐芦定（BEMICOP 研究）：一项开放标签、多中心、随机、对照试验。
Thromb Haemost. 2022 Feb;122(2):295-299. doi: 10.1055/a-1667-7534. Epub 2021 Dec 29.
2
Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial.COVID-19 住院高危患者中治疗剂量肝素与标准预防剂量或中剂量肝素预防血栓的疗效和安全性：HEP-COVID 随机临床试验。
JAMA Intern Med. 2021 Dec 1;181(12):1612-1620. doi: 10.1001/jamainternmed.2021.6203.
3
Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials.不同预防性抗凝剂量方案在 COVID-19 危重症和非危重症患者中的安全性和有效性：一项随机对照试验的系统评价和荟萃分析。
Eur Heart J Cardiovasc Pharmacother. 2022 Sep 29;8(7):677-686. doi: 10.1093/ehjcvp/pvab070.
4
Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19.COVID-19 非危重症患者的肝素治疗性抗凝。
N Engl J Med. 2021 Aug 26;385(9):790-802. doi: 10.1056/NEJMoa2105911. Epub 2021 Aug 4.
5
Myocardial Injury in COVID-19 Patients: Association with Inflammation, Coagulopathy and In-Hospital Prognosis.COVID-19患者的心肌损伤：与炎症、凝血功能障碍及住院预后的关系
J Clin Med. 2021 May 13;10(10):2096. doi: 10.3390/jcm10102096.
6
Coronavirus Disease 2019-Associated Thrombosis and Coagulopathy: Review of the Pathophysiological Characteristics and Implications for Antithrombotic Management.新型冠状病毒病相关血栓形成和凝血障碍：病理生理学特征综述及其对抗血栓治疗管理的影响。
J Am Heart Assoc. 2021 Feb 2;10(3):e019650. doi: 10.1161/JAHA.120.019650. Epub 2020 Nov 24.

Updated meta-analysis of randomized controlled trials on the safety and efficacy of different prophylactic anticoagulation dosing regimens in non-critically ill hospitalized patients with COVID-19.

作者信息

Ortega-Paz Luis, Galli Mattia, Angiolillo Dominick J

机构信息

Division of Cardiology, University of Florida College of Medicine, 5th floor, ACC Building, 655 West 8th Street, Jacksonville, FL 32209, USA.

Catholic University of the Sacred Heart, Rome, Italy.

出版信息

Eur Heart J Cardiovasc Pharmacother. 2022 May 5;8(3):E15-E17. doi: 10.1093/ehjcvp/pvac010.

DOI:10.1093/ehjcvp/pvac010
PMID:35108396
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9383405/
Abstract
摘要